The publication by Volpe et al., demonstrated that immunoPET targeting Inducible T-cell COStimulator (ICOS or CD278), a costimulatory molecule upregulated during T-cell activation, enables in vivo imaging of activated CAR T cells at the tumor site (Volpe et al. 2021). Here, ICOS is linked to neoplasm.